/
REPL
$11.20-$0.43 (-3.70%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$960.3M
83M shares
52-week range
$1.50 – $13.24
83% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $109.0K | $148.0K | $0 | $4.1M | $4.6M | $0 | $0 | $0 |
| Gross profit | −$109.0K | −$148.0K | $0 | −$4.1M | −$4.6M | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $13.5M | $22.2M | $38.8M | $57.5M | $80.6M | $126.5M | $175.0M | $189.4M |
| Operating income | −$19.2M | −$30.9M | −$56.2M | −$82.8M | −$121.5M | −$177.1M | −$234.8M | −$261.6M |
| EBITDA | −$16.9M | −$30.7M | −$52.6M | −$76.5M | −$114.4M | −$171.7M | −$227.8M | −$253.9M |
| Net income | −$19.7M | −$30.8M | −$52.6M | −$80.9M | −$118.0M | −$174.3M | −$215.8M | −$247.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.64 | -1.33 | -1.54 | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $18M | $-1.81 | $-2.19–$-1.06 | 5 |
| 2028 | $23M | $-1.18 | $-2.03–$-0.37 | 5 |
| 2029 | $103M | $-0.69 | $-1.20–$-0.01 | 4 |
| 2030 | $128M | $-0.42 | $-1.26–$0.05 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.33
Price
$11.20
Implied downside
-97%
Peer comparison
Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
www.replimune.com- Employees
- 479
- IPO / List date
- Jul 20, 2018
- HQ
- WOBURN, MA
Held by traders on TradeandTell
No one on the platform currently holds REPL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 381,453 | $2.9M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2010-12-01 | 15-for-1 |
Recent trades on TradeandTell
No one on the platform has traded REPL yet.
